Marina Biotech

Biotechnology, Health Care, Medical, Pharmaceutical
Founded in 1983-01-01
City Of Industry, California, United States
http://www.marinabio.com
For Profit

About Marina Biotech

Our mission is to provide effective and patient centric treatment for hypertension- including resistant hypertension. In doing so creating a universal platform for the effective treatment of hypertension as well as for the distribution of fixed dose combination [FDC] hypertensive drugs such as Prestalia® and those in our pipeline. The company commercial product Prestalia® is approved by US FDA for the treatment of hypertension and being commercialized through the DyrctAxess platform. The company is also developing and commercializing late stage, non-addictive pain therapeutics. The company’s ‘next-generation of celecoxib,’ including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combatting the opioid epidemic.

Company Metrics

  • Employees: 11-50
  • Monthly Visits: None
  • Tech Stack: 9 active products

Financial Information

  • Estimated Revenue: Less than $1M
  • Total Funding: 19900000 USD
  • Last Funding: 1500000 USD (Post-IPO Equity)
  • Funding Status: IPO

Technology Stack

Marina Biotech actively uses 9 products in their tech stack.

Market Presence

Industries: Biotechnology, Health Care, Medical, Pharmaceutical

Headquarters: City Of Industry, California, United States